TScan Shares Jump 23% on Securities Purchase Agreement

Dow Jones
2024-12-26
 

By Denny Jacob

 

TScan Therapeutics shares jumped 23% in premarket trading after a $30 million registered direct offering.

Shares were trading around $3.58. The stock is down about 50% on the year.

The Waltham, Mass.-based clinical-stage biotechnology company said it entered into a securities purchase agreement with Lynx1 Capital Management and investment fund advised by Lynx1 for the sale of about $30 million of pre-funded warrants to purchase up to an aggregate of 7.5 million shares of its voting common stock at a price of $4 per pre-funded warrant.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

December 26, 2024 09:13 ET (14:13 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10